KA2507

KA2507 is an orally bioavailable, potent, and selective small molecule inhibitor of histone deacetylase 6 (HDAC6). By targeting and inhibiting HDAC6, KA2507 leads to the accumulation of acetylated chromatin histones, resulting in chromatin remodeling and altered gene expression. This inhibition prevents STAT3 activity and reduces programmed death-1 (PD‑1) expression, promoting selective transcription of tumor suppressor genes and inducing apoptosis in tumor cells that overexpress HDAC6. Preclinical studies demonstrated antitumor efficacy as well as immune modulatory effects. In clinical trials, KA2507 was well tolerated with no significant toxicities observed up to the maximum administered dose. The drug was developed primarily for solid tumors such as advanced biliary tract cancer and melanoma[1][2][4][5][6].

Other names

1636894-46-6VQ7NU11KRMVQ-7NU11KRMVQ 7NU11KRMUNII-VQ7NU11KRMUNII-VQ-7NU11KRMUNII-VQ 7NU11KRM